← Lexeo Therapeutics, Inc. (LXEO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Lexeo Therapeutics, Inc. (LXEO)
Biological Products, (No Diagnostic Substances) · market cap $295M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Lexeo Therapeutics (LXEO) is a single-asset clinical-stage gene therapy company with 61 employees and a $376M market cap. Its lead and only disclosed program, LX1001, is in Phase 2 for Alzheimer's Disease. The company carries ~$71.8M in cash, implying roughly 10 months of runway at a ~$100M annual burn rate.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LX1001 | Phase 2 | Alzheimer Disease |
Price & technical context
3-month
-22.8%
6-month
-36.2%
12-month
-45.5%
52-wk range
$3.14–$10.63
vs 50-day MA
-18.6%
vs 200-day MA
-38.7%
Realized vol
75.1%
Max drawdown
-84.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LXEO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.